Literature DB >> 20383536

Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.

Atsushi Kanno1, Kennichi Satoh, Morihisa Hirota, Shin Hamada, Jun Umino, Hiromichi Itoh, Atsushi Masamune, Tohru Asakura, Tooru Shimosegawa.   

Abstract

BACKGROUND: Patients with branch duct type intraductal papillary mucinous neoplasm (BD-IPMN) without invasion usually show favorable prognosis. However, the prognosis becomes poor when the IPMN lesions give rise to invasive carcinoma cells. In addition, recent studies have revealed that BD-IPMN is frequently complicated by common type pancreatic ductal carcinoma. Thus, the prognosis of BD-IPMN depends on the occurrence of these two types of invasive carcinoma. However, little is known about the risk factors for the development of these invasive carcinomas in BD-IPMN. This study aims to identify the factors which predict the development of invasive carcinoma in BD-IPMN.
METHODS: Invasive pancreatic carcinoma associating with BD-IPMN was classified as invasive IPMN group (invasive carcinoma derived directly from IPMN lesions) and concomitant group (common type of invasive carcinoma concomitant with BD-IPMN). The relation between the incidence of each type of invasive carcinoma in BD-IPMN and the clinicopathological parameters was retrospectively analyzed.
RESULTS: There were 12 patients with invasive IPMN and 7 patients with concomitant cancer in 159 patients with BD-IPMN. Diameter of dilated branch (P < 0.001) or main pancreatic duct (MPD) (P = 0.001), size of mural nodule (P < 0.001), serum CEA level (P < 0.001) and serum CA19-9 level (P < 0.001) were factors associated significantly with invasive IPMN by univariate analysis. Among these factors, mural nodule with size larger than 6.5 mm [odds ratio 14.86 (95% CI 1.37-60.45); P = 0.02] and serum carcinoembryonic antigen (CEA) level over 5 ng/ml [odds ratio 6.91 (95% CI 1.17-54.13); P = 0.03] were found to be the factors independently associated with invasive IPMN. On the other hand, both univariate and multivariate analyses revealed that elevated carbohydrate antigen 19-9 (CA 19-9) levels were associated with the occurrence of concomitant ductal carcinoma in BD-IPMN [odds ratio 10.31 (95% CI 1.77-81.51); P = 0.01].
CONCLUSIONS: Our results suggested that careful imaging study of the entire pancreas in addition to tumor lesions and measurement of serum CEA and CA19-9 would be required to find out the development of the two types of invasive carcinoma in BD-IPMN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383536     DOI: 10.1007/s00535-010-0238-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas.

Authors:  Massimo Raimondo; Issei Tachibana; Raul Urrutia; Lawrence J Burgart; Eugene P DiMagno
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

4.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

5.  Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.

Authors:  M Sugiyama; Y Izumisato; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

6.  Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases.

Authors:  E Nagai; T Ueki; K Chijiiwa; M Tanaka; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  1995-05       Impact factor: 6.394

7.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.

Authors:  Hiroshi Ogawa; Shigeki Itoh; Mitsuru Ikeda; Kojiro Suzuki; Shinji Naganawa
Journal:  Radiology       Date:  2008-07-15       Impact factor: 11.105

9.  Invasive carcinoma derived from intraductal papillary mucinous carcinoma of the pancreas.

Authors:  Toshio Nakagohri; Masaru Konishi; Kazuto Inoue; Yutaka Tanizawa; Taira Kinoshita
Journal:  Hepatogastroenterology       Date:  2004 Sep-Oct

10.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  33 in total

Review 1.  [Intraductal papillary mucinous neoplasia: which findings support observation?].

Authors:  J Mayerle; M Kraft; P Menges; P Simon; J Ringel; L I Partecke; C D Heidecke; M M Lerch
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

2.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.

Authors:  Seiko Hirono; Yasuhiro Shimizu; Takao Ohtsuka; Toshifumi Kin; Kazuo Hara; Atsushi Kanno; Shinsuke Koshita; Keiji Hanada; Masayuki Kitano; Hiroyuki Inoue; Takao Itoi; Toshiharu Ueki; Toshio Shimokawa; Susumu Hijioka; Akio Yanagisawa; Masafumi Nakamura; Kazuichi Okazaki; Hiroki Yamaue
Journal:  J Gastroenterol       Date:  2019-08-28       Impact factor: 7.527

3.  Pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm: a report of 8 cases.

Authors:  Koichiro Mandai; Koji Uno; Kenjiro Yasuda
Journal:  Clin J Gastroenterol       Date:  2013-05-12

4.  Uncinate duct dilation in intraductal papillary mucinous neoplasms of the pancreas: a radiographic finding with potentially increased malignant potential.

Authors:  John B Ammori; Richard K G Do; Murray F Brennan; Michael I D'Angelica; Ronald P Dematteo; Yuman Fong; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2014-01-22       Impact factor: 3.452

5.  The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Kenjiro Kimura; Ryosuke Amano; Sadaaki Ymazoe; Go Ohira; Kohei Nishio; Kosei Hirakawa; Masaichi Ohira
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

Review 6.  International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Masao Tanaka
Journal:  Ann Transl Med       Date:  2015-11

7.  Predictors of early stages of histological progression of branch duct IPMN.

Authors:  Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Satoshi Iino; Yuko Kijima; Sumiya Ishigami; Shinichi Ueno; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  Langenbecks Arch Surg       Date:  2014-12-03       Impact factor: 3.445

8.  Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.

Authors:  Andrew H Nguyen; Paul A Toste; James J Farrell; Barbara M Clerkin; Jennifer Williams; V Raman Muthusamy; Rabindra R Watson; James S Tomlinson; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2014-11-06       Impact factor: 3.452

9.  Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Mathieu Daudé; Fabrice Muscari; Camille Buscail; Nicolas Carrère; Philippe Otal; Janick Selves; Louis Buscail; Barbara Bournet
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

10.  Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct.

Authors:  Klaus Sahora; Carlos Fernández-del Castillo; Fei Dong; Giovanni Marchegiani; Sarah P Thayer; Cristina R Ferrone; Dushyant V Sahani; William R Brugge; Andrew L Warshaw; Keith D Lillemoe; Mari Mino-Kenudson
Journal:  Surgery       Date:  2014-07-28       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.